Duolingo Stock Is Crashing! Buying Opportunity?
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 06 Aug 2026, 18:19 UTC
- Recorded by Tahlil Plus
- 06 Aug 2026, 20:23 UTC
AI-generated source summary
The analysis focuses on Duolingo's financial performance, highlighting revenue growth and user engagement. While revenue showed a 11.1% year-over-year increase in Q3 2026, total bookings growth was only 8%, which was viewed as a slight disappointment. The company is investing heavily in sales and marketing, with a 10 million increase in R&D spending. The CEO aims to reach 100 million daily active users, which is a significant growth target. The stock is trading at a forward P/S ratio of 4.52, considered cheap given the company's growth and high margins. The 'Streak Revival' campaign showed strong user engagement, with 15.4 million users reviving their streaks, indicating a sticky user base and gamified approach to learning. However, the deceleration in daily active user growth and paid subscriber growth is a concern. The analysis suggests that while the company is growing, its focus on user acquisition over short-term profitability might be a strategic gamble. The current stock price of $121.77 is seen as potentially undervalued given its growth prospects.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.